Page 1

eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET today • Management to host Q2 2026 update at 5PM ET / 2PM PT , today . Los Angeles , CA -- August 20 , 2026 -- Today , eXoZymes Inc. ( NASDAQ : EXOZ ) ( " eXoZymes " ) - a pioneer of Al - enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - will host an investor webinar today at 5:00 PM Eastern Time to discuss results for the second quarter ended June 30 , 2026 , and provide an update on recent business developments . Michael Heltzen , CEO of eXoZymes , states , " We have taken a molecule from concept to pilot validation and now beyond our original commercial economic targets in less than two years . That speed is exactly what I believe can make eXoZymes commercially differentiated : getting high - value nutraceutical and pharmaceutical molecules to attractive markets faster , with the potential to create meaningful opportunities for our partners and significant value for our shareholders . And most importantly , we believe this is a process we can repeat across other high - value molecules in our pipeline . " Second quarter 2026 highlights : • Lead NCT program advances beyond original commercial economic targets : eXoZymes ' optimized NCT process just delivered a 10 - fold increase in manufacturing productivity since the pilot scale , via producing approximately 67 % more NCT per liter , while reducing reaction time by over 80 % . The improvements advance NCT beyond the Company's original commercial - scale economic targets , further strengthening the technology for transfer and commercial manufacturing . • Strengthened capital position : In June , eXoZymes completed an underwritten public offering generating approximately $ 6 million in gross proceeds , strengthening the Company's capital position as it advances NCT toward commercialization , develops additional high - value molecules from its platform and continues investing in research and development . The financing provides additional resources to execute against the Company's near - term development and commercialization priorities . • $ 2 million NIH grant supports pharmaceutical development strategy : In June , eXoZymes was awarded an approximately $ 2 million Phase IIB Small Business Innovation Research ( SBIR ) grant from the National Institutes of Health ( NIH ) to advance the preclinical development of novel cannabinoid analogs . The two - year award provides non - dilutive funding to support the Company's pharmaceutical development strategy while further validating the potential of eXoZymes ' platform to rapidly produce and evaluate new - to - nature molecules with potential therapeutic applications . • Operational and financial update : Operating expenses for the second quarter of 2026 were $ 2.95 million , compared with $ 2.55 million for the same period in 2025. Net loss was $ 2.88 million for the quarter and $ 5.25 million for the six months ended June 30 , 2026 . The Company ended the quarter with $ 5.65 million in cash and cash equivalents , which the Company expects will support operations through the end of 2026 . Investors and interested parties can access the live webinar , at the time of the event through eXoZymes ' website . A recording of the conference call will also be made publicly available relatively soon after the live call .